Suppr超能文献

肠道微生物群:儿童梨形鞭毛虫病治疗的新靶点?

Intestinal microbiome: a new target for chalaziosis treatment in children?

机构信息

Department of Medicine and Health Sciences "V. Tiberio", University of Molise, Campobasso, Molise, Italy.

R&D Department, PROBIOTICAL RESEARCH Srl, Novara, Piemonte, Italy.

出版信息

Eur J Pediatr. 2021 Apr;180(4):1293-1298. doi: 10.1007/s00431-020-03880-5. Epub 2020 Nov 23.

Abstract

Intestinal dysbiosis (changes in the gut commensal microbiome) is related to several ophthalmic diseases. The aim of this study was to verify whether oral specific probiotics can alter the clinical course of chalaziosis and its recurrence. A prospective comparative pilot study involving 26 children suffering from chalaziosis was conducted. Children were randomly divided into two groups. The first group received medical treatment (lid hygiene, warm compression and dexamethasone/tobramycin ointment for at least 20 days), and the second group received medical treatment plus a daily supplementation of oral probiotics (≥ 1 × 10^9 live cells of Streptococcus thermophilus ST10 (DSM 25246), ≥ 1 × 10^9 live cells of Lactococcus lactis LCC02 (DSM 29536) and ≥ 1 × 10^9 live cells of Lactobacillus delbrueckii subsp. bulgaricus (DSM 16606) with maltodextrin as the bulking agent (Probiotical S.p.A., Novara, Italy). All patients were evaluated at 2-week intervals for 3 months. If the lesion had not disappeared or decreased in size to 1 mm or less in diameter at the time of subsequent visits, the same procedure was repeated for another 3-month cycle. There was a significant difference in the time taken for complete resolution of the chalazion between the two groups in favour of the children receiving the probiotics. The treatment was not associated with any significant complications in either group. Trial registration: The trial was registered at clinical trials.gov under NCT04322500 on 25/03/2020 ("retrospectively registered").Conclusions: Modification of the intestinal microbiome with specific probiotics can alter the clinical course of chalaziosis in children by re-establishing intestinal and immune homeostasis. Probiotic supplementation can increase the effectiveness of traditional therapies by prompting the complete resolution of chalaziosis in a shorter amount of time, in an easy and feasible way. What is Known: • The intestinal microbiome plays a crucial role in several inflammatory diseases of the eye and is considered a therapeutic target. • Probiotics play a role in the prevention and treatment of different conditions in children. What is New: • In children probiotic supplementation is safe and effective. • Probiotic supplementation reduced the time required for complete resolution of the chalazion.

摘要

肠道菌群失调(肠道共生微生物组的变化)与多种眼科疾病有关。本研究旨在验证口服特定益生菌是否能改变儿童麦粒肿的临床病程及其复发情况。进行了一项涉及 26 名患有麦粒肿的儿童的前瞻性对照性试点研究。儿童被随机分为两组。第一组接受药物治疗(眼睑卫生、热敷和地塞米松/妥布霉素眼膏至少 20 天),第二组接受药物治疗加每日口服益生菌补充剂(≥1×10^9 活细胞嗜热链球菌 ST10(DSM 25246)、≥1×10^9 活细胞乳酸乳球菌 LCC02(DSM 29536)和≥1×10^9 活细胞德氏乳杆菌保加利亚亚种(DSM 16606),用麦芽糊精作为赋形剂(Probiotical S.p.A.,诺瓦拉,意大利)。所有患者在 3 个月内每 2 周评估一次。如果在后续就诊时病变未消失或大小未减小至 1 毫米或更小,则对同一病变重复另一个 3 个月的周期。在两组中,益生菌组完全消退的时间明显短于对照组。两组均未出现任何与治疗相关的严重并发症。试验注册:该试验于 2020 年 3 月 25 日在 clinicaltrials.gov 上注册(NCT04322500,“事后注册”)。结论:用特定益生菌改变肠道微生物组可以通过重新建立肠道和免疫稳态来改变儿童麦粒肿的临床病程。益生菌补充剂可以通过促使麦粒肿更快完全消退,从而提高传统疗法的有效性,而且这种方法简单易行。已知情况:肠道微生物组在眼部的几种炎症性疾病中起着至关重要的作用,被认为是一个治疗靶点。益生菌在儿童的不同疾病的预防和治疗中发挥作用。新情况:益生菌补充剂在儿童中是安全且有效的。益生菌补充剂减少了麦粒肿完全消退所需的时间。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验